KR102610870B1 - 편두통 예방 및 치료 - Google Patents

편두통 예방 및 치료 Download PDF

Info

Publication number
KR102610870B1
KR102610870B1 KR1020197021346A KR20197021346A KR102610870B1 KR 102610870 B1 KR102610870 B1 KR 102610870B1 KR 1020197021346 A KR1020197021346 A KR 1020197021346A KR 20197021346 A KR20197021346 A KR 20197021346A KR 102610870 B1 KR102610870 B1 KR 102610870B1
Authority
KR
South Korea
Prior art keywords
βhb
migraine
pharmaceutical composition
salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197021346A
Other languages
English (en)
Korean (ko)
Other versions
KR20190099486A (ko
Inventor
엘레나 그로스
디르크 피셔
Original Assignee
우니베르지태츠-킨데르슈피탈 바이더 바젤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우니베르지태츠-킨데르슈피탈 바이더 바젤 filed Critical 우니베르지태츠-킨데르슈피탈 바이더 바젤
Publication of KR20190099486A publication Critical patent/KR20190099486A/ko
Application granted granted Critical
Publication of KR102610870B1 publication Critical patent/KR102610870B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197021346A 2016-12-21 2017-12-20 편두통 예방 및 치료 Active KR102610870B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16206018 2016-12-21
EP16206018.0 2016-12-21
EP17154258 2017-02-01
EP17154258.2 2017-02-01
PCT/EP2017/083880 WO2018115158A1 (en) 2016-12-21 2017-12-20 Migraine prevention and treatment

Publications (2)

Publication Number Publication Date
KR20190099486A KR20190099486A (ko) 2019-08-27
KR102610870B1 true KR102610870B1 (ko) 2023-12-06

Family

ID=61005774

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197021346A Active KR102610870B1 (ko) 2016-12-21 2017-12-20 편두통 예방 및 치료

Country Status (17)

Country Link
US (2) US11166928B2 (https=)
EP (2) EP3558280B1 (https=)
JP (2) JP7514457B2 (https=)
KR (1) KR102610870B1 (https=)
CN (1) CN110087642B (https=)
AU (2) AU2017384625B2 (https=)
CA (1) CA3046415A1 (https=)
DK (1) DK3558280T3 (https=)
ES (1) ES2948609T3 (https=)
FI (1) FI3558280T3 (https=)
HR (1) HRP20230851T1 (https=)
HU (1) HUE062536T2 (https=)
LT (1) LT3558280T (https=)
PL (1) PL3558280T3 (https=)
RU (1) RU2753057C9 (https=)
SI (1) SI3558280T1 (https=)
WO (1) WO2018115158A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
EP3558280B1 (en) * 2016-12-21 2023-06-07 Universitäts-kinderspital Beider Basel Migraine prevention and treatment
US20180177753A1 (en) 2016-12-23 2018-06-28 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for migraine symptom management
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
BR112021015861A2 (pt) * 2019-03-22 2021-10-05 Société des Produits Nestlé S.A. Métodos que usam administração de triglicerídeos de cadeia média (tcm) antes de uma refeição para aumentar a produção de cetonas a partir dos tcms
EP3965740A1 (en) 2019-05-10 2022-03-16 KetoSwiss AG Ketone bodies enclosed in microbeads
EP4656238A3 (de) * 2019-06-12 2026-02-25 KetoLipix Therapeutics GmbH Verfahren zur herstellung von acylverkappten 3-hydroxycarbonsäuren sowie deren salzen und estern
CN114008014B (zh) * 2019-06-12 2024-03-22 凯托利皮克斯治疗有限责任公司 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法
WO2021195477A1 (en) 2020-03-27 2021-09-30 Ketoneaid, Inc. Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections
KR20240037239A (ko) 2021-07-17 2024-03-21 케토스위스 아게 케톤체 또는 케톤 생성 화합물과 진통제 또는 항산화제의 조합
CN119072305A (zh) 2022-03-02 2024-12-03 N·V·努特里奇亚 用于控制酮症的脂肪酸
CN115590963A (zh) * 2022-07-13 2023-01-13 复旦大学（Cn） 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用
KR102775899B1 (ko) 2023-12-19 2025-02-28 한림대학교 산학협력단 삽화성 편두통 및 만성 편두통 진단을 위한 정보제공 방법, 장치 및 컴퓨터 프로그램

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011294A1 (en) * 2015-07-10 2017-01-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone esters, and other ketogenic sources

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174979A4 (en) * 1984-03-01 1987-11-23 Vernon Erk METHOD FOR LOWERING THE BLOOD GLUCOSE LEVEL IN VERBELTIES.
JPH0665458A (ja) * 1992-08-21 1994-03-08 Nippon Oil & Fats Co Ltd 塩素含有樹脂組成物
US5420335A (en) * 1993-09-30 1995-05-30 Birkhahn; Ronald H. Parenteral nutrients based on watersoluble glycerol bisacetoacetates
CA2283642C (en) * 1997-03-17 2012-05-15 Btg International Limited Therapeutic compositions
WO2000015216A1 (en) * 1998-09-15 2000-03-23 Btg International Limited Therapeutic compositions (ii)
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US7807718B2 (en) * 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
WO2010084356A1 (en) * 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
CN103877118A (zh) * 2014-03-11 2014-06-25 天津金耀集团有限公司 一种由醋丙甲泼尼龙、氧化锌组成的药物组合物
US20160078782A1 (en) * 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
EP3558280B1 (en) * 2016-12-21 2023-06-07 Universitäts-kinderspital Beider Basel Migraine prevention and treatment
US20180177753A1 (en) 2016-12-23 2018-06-28 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for migraine symptom management
US10500182B2 (en) 2018-01-10 2019-12-10 Robert Firger Compositions of ketogenic sources, micronutrients and phytochemicals for prophylaxis and mitigation of migraine headache

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011294A1 (en) * 2015-07-10 2017-01-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone esters, and other ketogenic sources

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
European Journal of Neurology 2015, 22, 170~177

Also Published As

Publication number Publication date
CN110087642B (zh) 2022-12-27
US20210338618A1 (en) 2021-11-04
AU2017384625A1 (en) 2019-06-13
EP4245368A3 (en) 2024-01-03
FI3558280T3 (fi) 2023-07-13
US20190374490A1 (en) 2019-12-12
US11166928B2 (en) 2021-11-09
AU2022201565A1 (en) 2022-03-31
EP3558280A1 (en) 2019-10-30
JP7514457B2 (ja) 2024-07-11
RU2753057C2 (ru) 2021-08-11
CN110087642A (zh) 2019-08-02
JP2022166218A (ja) 2022-11-01
CA3046415A1 (en) 2018-06-28
AU2022201565B2 (en) 2023-07-06
EP3558280B1 (en) 2023-06-07
HRP20230851T1 (hr) 2023-11-10
KR20190099486A (ko) 2019-08-27
WO2018115158A1 (en) 2018-06-28
DK3558280T3 (da) 2023-08-21
HUE062536T2 (hu) 2023-11-28
JP2020504746A (ja) 2020-02-13
RU2019122562A (ru) 2021-01-27
PL3558280T3 (pl) 2023-10-16
EP4245368A2 (en) 2023-09-20
RU2019122562A3 (https=) 2021-01-27
ES2948609T3 (es) 2023-09-14
SI3558280T1 (sl) 2023-10-30
US11890264B2 (en) 2024-02-06
LT3558280T (lt) 2023-10-10
RU2753057C9 (ru) 2021-09-10
AU2017384625B2 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
KR102610870B1 (ko) 편두통 예방 및 치료
Cunnane et al. Can ketones help rescue brain fuel supply in later life? Implications for cognitive health during aging and the treatment of Alzheimer’s disease
Dupont et al. Sustained‐release Madopar HBS® compared with standard Madopar® in the long‐term treatment of de novo parkinsonian patients
Page et al. Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia
Stafstrom Dietary approaches to epilepsy treatment: old and new options on the menu
Fernstrom Effects and side effects associated with the non-nutritional use of tryptophan by humans
Pezzoli et al. Levodopa in Parkinson's disease: from the past to the future
JP2018184440A (ja) うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US20070179197A1 (en) Compositions and methods for improving or preserving brain function
JP2018131470A (ja) グルコーストランスポータ１欠乏の治療のためのトリヘプタノイン
Stacy et al. Apomorphine for the acute treatment of “off” episodes in Parkinson's disease
JP7481402B2 (ja) 皮膚疾患の処置のための併用療法
Jost et al. Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease
KR20110043648A (ko) 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
Chen et al. Synergistically effects of n-3 PUFA and B vitamins prevent diabetic cognitive dysfunction through promoting TET2-mediated active DNA demethylation
Watson et al. Is there a role for ketones as alternative fuel in critical illness?
Mundt-Petersen et al. Infusional therapies, continuous dopaminergic stimulation, and nonmotor symptoms
Bourque et al. The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys
Pokora et al. The ketogenic diet in Parkinson’s disease: a potential therapeutic strategy
Abd Alkareem et al. Metformin and Omega 3 effect on Cholesterol and HDL level in Iraqi women with Poly Cystic Ovary Syndrome
White et al. Novel Metabolic Substrates for Feeding the Injured Brain
JP2026058735A (ja) 睡眠の質改善用組成物
Cunnane et al. St-Pierre V

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601